drugset / Trial / NCT00277498

A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

NCT00277498

Phase 3 Completed 528 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.

Timeline

Start
2005-12
Primary completion
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Latanoprost Small molecule
Subject Timolol Other / unclassified